Cancer Biomarker Detection With Luminex Assays
Luminex and Bio-Techne are working together to support the development of early diagnostic solutions that detect cancer earlier through the use of proteomics.
Charles Rosser, a research scientist and professor of biomedical sciences, has developed a multiplex test for early-stage bladder cancer using Luminex® xMAP® Technology. Bladder cancer affects over 570,000 people globally each year, and the Oncuria® test aims to detect bladder cancer, monitors for recurrence, and predicts which patients will benefit from the immunotherapy treatment. Current diagnostic assays lack sensitivity and do not provide a comprehensive view of the cancer’s molecular profile, but the Oncuria® test covers 10 glycoproteins to detect the biological signature of bladder cancer with sensitivity of 90% to 93% and specificity of 86% to 95%. The test received Breakthrough Device Designation status from the FDA and is currently available as a laboratory-developed test (LDT). In a recent clinical validation study involving about 350 patients, the test offered 93% sensitivity. Learn more about this major shift in the care of patients with bladder cancer.
Luminex Assay, Luminex Cytokine Assay, Luminex ELISA Multiplex
MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel II - Premixed 23 Plex - Immunology Multiplex Assay
Cancer Biomarker Detection With Luminex Assays
Lipid Metabolism Pathway Luminex Multiplex Assay - Creative Proteomics
Multiplexed Profiling of Extracellular Vesicles for Biomarker Development
Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy
Multiplex Analysis of Secreted Biomarkers from Stimulated Natural Killer Cells: R&D Systems
Human Luminex Discovery Assay (LXSAHM): R&D Systems
Multiplex biomarker approach to cardiovascular diseases
